Zoll CEO Rick Packer says that tax repeal advocates on the front lines of the discussions with Washington are optimistic that the levy on device makers will be addressed before it hits in January.
As the medical device excise tax creeps closer to its planned launch date, all eyes are on Congress to see whether medtech lobbying efforts will yield a win for the industry.
While lawmakers weigh the tax and argue their way toward the so-called fiscal cliff, device industry stakeholders are placing their bets on whether or not the excise tax will survive until January.
In this MassDevice Big 100 West preview, we talk to Strathspey Crown Chairman Robert Grant about how his private equity firm Strathspey Crown is looking to break the mold.
In this MassDevice Big 100 West preview we talk to Align Technology CEO Tom Prescott about how Invisalign crossed the chasm into mainstream culture through social media and aggressive consumer marketing strategies.
Medical device company Sanovas is looking to raise about $25 million to commercialize its next-generation Vas Zeppelin pulmonary device designed to scan, diagnose and treat lung disease in a single sitting.
Most startup medical device companies raise 10s of millions to research and develop their products before they even get to the commercial stage. But for Sanovas and co-founder Larry Gerrans, the 12-year journey to that point required a scant $9 million – all raised from the pulmonary device firm's founders, friends and family, Gerrans told MassDevice.com last month.
"We've built the company with significant...
OmniGuide CEO Scott Flora tells MassDevice.com about his plans to build commercial scale for its BeamPath surgical laser.
MassDevice.com first visited OmniGuide in 2009, when the Cambridge, Mass.-based medical device company was developing the BeamPath laser scalpel, aiming for 2 orders of magnitude more precision than the most precise soft-tissue cutting tool.
Today the company has refined that technology even further and has turned its focus toward ramping up commercialization of the BeamPath device, CEO Scott Flora told us this month.
Medtech veteran Christopher Jones, the CEO of medical device company GlySure, tells MassDevice.com about his experiences in the U.S. and across the pond, with some words of guidance for companies pursuing a Europe-1st strategy.
GlySure CEO Christopher Jones has a career spanning more than 2 decades and 2 continents, during which he's seen the medtech regulatory pendulum swing from the Europe to the U.S. and back.
In an exclusive interview with MassDevice.com, Jones told us about being an American executive in the U.K., changing regulatory timelines and challenges to look for with a Europe-1st strategy.